RELETRANS

This brand name is authorized in Ireland, United Kingdom

Active ingredients

The drug RELETRANS contains one active pharmaceutical ingredient (API):

1 Buprenorphine UNII 40D3SCR4GZ - BUPRENORPHINE

Buprenorphine is an opioid partial agonist/antagonist which attaches itself to the μ (mu) and κ (kappa) receptors of the brain. Its activity in opioid maintenance treatment is attributed to its slowly reversible link with the μ receptors which, over a prolonged period, minimises the need of illicit opioids for patients with opioid dependence. Read about Buprenorphine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RELETRANS Transdermal patch	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N02AE01	Buprenorphine	N Nervous system → N02 Analgesics → N02A Opioids → N02AE Oripavine derivatives
Discover more medicines within N02AE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 330388, 330390, 330392, 330394
Country: IE	Health Products Regulatory Authority	Identifier(s): 42726, 42727, 42728, 42729